ArticleThe World Allergy Organization journal2022
Dupilumab: An emerging therapy in allergic fungal rhinosinusitis.
Article in The World Allergy Organization journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Innate airway immune response to fungal allergens.Frontiers in immunology · 2026Review
- Persistent presumed allergic fungal rhinosinusitis during tezepelumab therapy with improvement after revision surgery: a case report.Frontiers in allergy · 2026Article
- Clinicopathological and microbiological study of fungal rhinosinusitis treated with endoscopic surgery.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2025Article
- Utilization of dupilumab in an immunocompromised patient with extensive allergic fungal rhinosinusitis unsuitable for surgical intervention: A case report.International journal of surgery case reports · 2025Article
- TThe Journal of allergy and clinical immunology · 2024Review
- Management of chronic rhinosinusitis with nasal polyps in the Asia-Pacific region and Russia: Recommendations from an expert working group.Asia Pacific allergy · 2024Review
- Biologic Therapies across Nasal Polyp Subtypes.Journal of personalized medicine · 2024Review
- The Effectiveness of Biological Agents on Chronic Rhinosinusitis with Nasal Polyposis in Patients with Comorbid Asthma: A Multicenter Real-Life Study from Türkiye.Medicina (Kaunas, Lithuania) · 2024Article
- Management of CRSwNP in Latin America: A multidisciplinary consensus from an expert working group.The World Allergy Organization journal · 2024Review
- Emerging Therapies in the Medical Management of Allergic Fungal Rhinosinusitis.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2024Article
- New Developments in Allergic Fungal Rhinosinusitis Pathophysiology and Treatment.American journal of rhinology & allergy · 2023Review
- Management of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in the Pan-Arab Region: Consensus Recommendations from a Multidisciplinary Expert Working Group.Journal of asthma and allergy · 2023Article
- The Effectiveness of Dupilumab in Treating Pediatric Refractory Allergic Fungal Rhinosinusitis.Therapeutic advances in allergy and rhinologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic fungal rhinosinusitis (AFRS) is a highly resistant disease and is challenging to treat. Patients with recurrent attacks of the disease despite surgical management can benefit from biologics as adjunct therapies. Dupilumab has shown promising endpoints in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). This case series reports 4 patients with resistant AFRS concomitant with asthma, for which dupilumab therapy was administered. Long-term follow-ups showed that dupilumab improved the symptoms and improved the results of objective tools such as imaging and pulmonary function test.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.